Oral Misoprostol for Outpatient Induction of Labor

Overview

An increasing proportion of pregnant women have their labors induced due to changing guidelines. In correlation with this increase, the population of the induced women has changed toward more women with a low-risk pregnancy. Traditionally, induction of labor has taken place in an inpatient setting where the women have spent extra days in hospital before delivery. Oral prostaglandins, such as misoprostol, is one of the most commonly used induction agent and is easy for the pregnant women to administrate. The pharmacological effect is ripening the cervix and compared to the mechanical cervical ripening, with a balloon catheter, the demands on busy maternity services seems reduced. Before contractions start, the risk of adverse effects on mother or fetus is considered low, but the evidence on use of misoprostol in an outpatient setting is sparse.

Full Title of Study: “Oral Misoprostol for Outpatient Induction of Labor; a Pilot Randomized-controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 15, 2021

Detailed Description

The implementation of induction of labor in outpatient settings is increasing despite insufficient evidence regarding safety and effectiveness. The use of a balloon catheter in an outpatient setting is not associated with adverse outcomes in a low-risk population. There is also evidence that outpatient vs inpatient induction of labor with balloon catheter is equally effective. Examination of vaginal dinoprostone (prostaglandin E2) is found to be efficacious in outpatient settings. However, strong evidence concludes that the oral route of administration of prostaglandin is preferable when inducing labor. The World Health Organization recommend 25ug misoprostol (prostaglandin E1) orally every 2 hour until contractions start for induction of labor. The women randomized to an inpatient setting will receive the hospital standard follow-up; oral misoprostol 25ug every two hours and a cardiotocography for fetal monitoring every 4-6 hour until start of contractions for two days. The women randomized to an outpatient setting will receive one oral misoprostol 25ug at the maternity unit. After two hours, provided a normal cardiotocography and no contractions, they can go home. They will continue to take 25ug misoprostol every two hours until start of contractions or increasing pain. Maximum time spent at home will be 48 hours. A dedicated midwife on call will always be available for questions. The women will receive oral and written information to return to the maternity unit if the water breaks, if they experience increasing pain or bleeding, if they feel insecure or anxious, if there are reduced or no fetal movements, and/or when the contraction starts. When the woman returns, she will stay admitted until delivery. All women will be given standard of care and fetal surveillance when admitted to the hospital, when the contractions start or if the contractions are still absent after 48 hours. We will also ask eligible women who refrain to participate about their reasons for non-participation. PRIMARY RESEARCH QUESTION We aim to explore that induction of labor using oral misoprostol appears feasible in an outpatient setting and may positively influence the length of the hospital stay and maternal satisfaction. PRIMARY RESEARCH PLAN This is a pilot study to explore the feasibility of a possible multicenter randomized controlled trail.

Interventions

  • Other: Inpatient setting
    • These women stay at the hospital.
  • Other: Outpatient setting
    • These women can leave the hospital.

Arms, Groups and Cohorts

  • Active Comparator: Induction of labour with oral misoprostol, inpatient setting
    • These women receive all treatment in the maternity unit.
  • Experimental: Induction of labour with oral misoprostol, outpatient setting
    • These women will be observed 2 hours after they receive one dose of oral misoprostol before the can leave the maternity unit.

Clinical Trial Outcome Measures

Primary Measures

  • The feasibility of a randomised controlled trial of outpatient labor induction
    • Time Frame: 6 months
    • The number of eligible women who is willing to enrol in participating

Secondary Measures

  • Reported labor experience among the women participating
    • Time Frame: From included in the study until postpartum discharge (1-2 weeks)
    • The women will fill out a survey before and after birth (including childbirth expectations, experience and satisfaction)
  • Maternal length of hospital stay
    • Time Frame: From included in the study until postpartum discharge (1-2 weeks)
    • Length of hospital stay form start of induction to postpartum discharge
  • Use of analgesia
    • Time Frame: From start of the partogram until birth (hours)
    • Use of epidural and fentanyl analgesia during labor

Participating in This Clinical Trial

Inclusion Criteria

  • Understand and read Norwegian – No cognitive barriers. The woman must be able to give informed consent – ≥ 37 gestational week, vertex presentation, single pregnancy – Normal ultrasound including fetal movements, amniotic fluid, estimated fetal weight +/- 15% (≤ 10 percentile and ≥ 90) and normal doppler peak systolic index in the umbilical cord artery and the cerebri media artery – Normal cardiotocography – Body Mass Index 18-35 – No signs of infection or health problems – Distance to hospital 45-60 minutes Exclusion Criteria:

  • Premature rupture of membranes – Previous cesarean section or operation on uterus – Fetal anomaly or chromosome/genetic disorder – Pregnancy complications such as preeclampsia and diabetes (insulin dependent) or other conditions were changes in fetal heart rate during labor is suspected – Not eligible for misoprostol as induction agent due a favorable cervix (Bishop score) and/or previous obstetric history

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sorlandet Hospital HF
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Janne Rossen, MD, PhD, Principal Investigator, Sorlandet Hospital Trust, Kristiansand, Norway

References

Vogel JP, Osoti AO, Kelly AJ, Livio S, Norman JE, Alfirevic Z. Pharmacological and mechanical interventions for labour induction in outpatient settings. Cochrane Database Syst Rev. 2017 Sep 13;9:CD007701. doi: 10.1002/14651858.CD007701.pub3. Review.

Alfirevic Z, Aflaifel N, Weeks A. Oral misoprostol for induction of labour. Cochrane Database Syst Rev. 2014 Jun 13;(6):CD001338. doi: 10.1002/14651858.CD001338.pub3. Review.

WHO Recommendations for Induction of Labour. Geneva: World Health Organization; 2011.

Diederen M, Gommers J, Wilkinson C, Turnbull D, Mol B. Safety of the balloon catheter for cervical ripening in outpatient care: complications during the period from insertion to expulsion of a balloon catheter in the process of labour induction: a systematic review. BJOG. 2018 Aug;125(9):1086-1095. doi: 10.1111/1471-0528.15047. Epub 2018 Jan 10.

Wilkinson C, Bryce R, Adelson P, Turnbull D. A randomised controlled trial of outpatient compared with inpatient cervical ripening with prostaglandin E₂ (OPRA study). BJOG. 2015 Jan;122(1):94-104. doi: 10.1111/1471-0528.12846. Epub 2014 May 14.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.